Microarray analysis reveals pivotal divergent mRNA expression profiles early in the development of either compensated ventricular hypertrophy or heart failure

Physiological Genomics

Volumn 21, Issue , 2005, Pages 314-323

  Buermans, Henk P J ^a   Redout, Everaldo M ^a   Schiel, Anja E ^a   Musters, René J P ^a   Zuidwijk, Marian ^a   Eijk, Paul P ^a   Van Hardeveld, Cornells ^a   Kasanmoentalib, Soemini ^a   Visser, Frans C ^b   Ylstra, Bauke ^a   Simonides, Warner S ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Apoptosis; Compensated hypertrophy; Early time point; Mitogen activated protein kinase signaling

Indexed keywords

MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; MONOCROTALINE; PYRROLIZIDINE ALKALOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DNA MICROARRAY; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEART VENTRICLE; HEART VENTRICLE HYPERTROPHY; MALE; MITOCHONDRION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ANIMALS; ATRIAL NATRIURETIC FACTOR; CALCIUM-TRANSPORTING ATPASES; DISEASE MODELS, ANIMAL; DNA PRIMERS; GENE EXPRESSION PROFILING; HEART FAILURE, CONGESTIVE; HYPERTENSION; HYPERTENSION, PULMONARY; HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; RATS; RATS, WISTAR; RNA; RNA, MESSENGER; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES;

RATTUS NORVEGICUS;

EID: 21244469404     PISSN: 15312267     EISSN: None     Source Type: Journal    
DOI: 10.1152/physiolgenomics.00185.2004     Document Type: Article

References (51)

1. Bernocchi P, Ceconi C, Pedersini P, Pasini E, Curello S, and Ferrari R. Skeletal muscle metabolism in experimental heart failure. J Mol Cell Cardiol 28: 2263-2273, 1996.
2. Brunner F, Wolkart G, and Haleen S. Defective intracellular calcium handling in monocrotaline-induced right ventricular hypertrophy: protective effect of long-term endothelin-A receptor blockade with 2-benzo[1,3]dioxol-5-yl- 3-benzyl-4-(4-methoxy-phenyl-)-4-oxobut-2-enoate-sodium (PD 155080). J Pharmacol Exp Ther 300: 442-449, 2002.
3. Bueno OF, De Windt LJ, Lim HW, Tymitz KM, Witt SA, Kimball TR, and Molkentin JD. The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo. Circ Res 88: 88-96, 2001.
4. Ceconi C, Condorelli E, Quinzanini M, Rodella A, Ferrari R, and Harris P. Noradrenaline, atrial natriureti: peptide, bombesin and neurotensin in myocardium and blood of rats in congestive cardiac failure. Cardiovasc Res 23: 674-682, 1989.
5. Chien KR. Molecular biology of cardiac hypertrophy and heart failure. In: Molecular Basis of Cardiovascular Disease, edited by Grace AA and Hunter JJ. Philadelphia, PA: WB Saunders, 1999, chapt. 9, p. 211-250.
6. Condorelli G, Morisco C, Stassi G, Nolle A, Farina F, Sgaramella G, de Rienzo A, Roncarati R, Trimarco B, and Lembo G. Increased cardiomyocyte apoptosis and changes in proapoptotic and antiapoptotic genes bax and bcl-2 during left ventricular adaptations to chronic pressure overload in the rat. Circulation 99: 3071-3078, 1999.
7. Crompton M, Barksby E, Johnson N, and Capano M. Mitochondrial intermembrane junctional complexes and their involvement in cell death. Biochimie 84: 143-152, 2002.
8. Doggrell SA and Brown L. Rat models of hypertension, cardiac hypertrophy and failure. Cardiovasc Res 39: 89-105, 1998.
9. Eaton S. Control of mitochondrial β-oxidation flux. Prog Lipid Res 41: 197-239, 2002.
10. Ecarnot-Laubriet A, Assem M, Poirson-Bichat F, Moisant M, Bernard C, Lecour S, Solary E, Rochelle L, and Teyssier JR. Stage-dependent activation of cell cycle and apoptosis mechanisms in the right ventricle by pressure overload. Biochim Biophys Acta 1586: 233-242, 2002.
11. Edgar R, Domrachev M, and Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: 207-210, 2002.
12. Ekstrand MI, Falkenberg M, Rantarien A, Park CB, Gaspari M, Hultenby K, Rustin P, Gustafsson CM, and Larsson NG. Mitochondrial transcription factor A regulates mtDNA copy number in mammals. Hum Mol Genet 13: 935-944, 2004.
13. Flashman E, Redwood C, Moolman-Smook J, and Watkins H. Cardiac myosin binding protein C: its role in phys.iology and disease. Circ Res 94: 1279-1289, 2004.
14. Fosslien E. Review: Mitochondrial medicine-cardiomyopathy caused by defective oxidative phosphorylation. Ann Clin Lab Sci 33: 371-395, 2003.
15. Frey N and Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 65: 45-79, 2003.
16. Fuller SJ, Davies EL, Gillespie-Brown J, Sun H, and Tonks NK. Mitogen-activated protein kinase phosphatase 1 inhibits the stimulation of gene expression by hypertrophic agonists in cardiac myocytes. Biochem J 323: 313-319, 1997.
17. Galland S, Georges B, Le Borgne F, Conductier G, Dias JV, and Demarquoy J. Thyroid hormone controls carnitine status through modifications of gamma-butyrobetaine hydroxylase activity and gene expression. Cell Mol Life Sci 59: 540-545, 2002.
18. Garnier A, Fortin D, Delomenie C, Momken I, Veksler I, and Ventura-Clapier R. Depressed mitochondrial transcription factors and oxidative capacity in rat failing cardiac and skeletal muscles. J Physiol 551: 491-501, 2003.
19. Gill SS, Pulido OM, Mueller RW, and McGuire PF. Immunochemical localization of the metabotropic glutamate receptors in the rat heart. Brain Res Bull 48: 143-146, 1999.
20. Gonzalez-Juanatey JR, Pineiro R, Iglesias MJ, Gualillo O, Kelly PA, Dieguez C, and Lago F. GH prevents apoptosis in cardiomyocytes cultured in vitro through a calcineurin-dependent mechanism. J Endocrinol 180: 325-335, 2004.
21. Heidebreder M, Frolich F, Johren O, Dendorfer A, Qadri F, and Dominiak P. Hypoxia rapidly activates HIF-3α mRNA expression. FASEB J 17: 1541-1543, 2003.
22. Hudig F, Bakker O, and Wiersinga WM. Amiodarone decreases gene expression of low-density lipoprotein receptor at both the mRNA and the protein level. Metabolism 47: 1052-1057, 1998.
23. Jones JE, Mendes L, Rudd MA, Russo G, Loscalzo J, and Zhang YY. Serial noninvasive assessment of progressive pulmonary hypertension in a rat model. Am J Physiol Heart Circ Physiol 283: H364-H371, 2002.
24. Kaiser RA, Bueno OF, Lips DJ, Doevendans PA, Jones F, Kimball TF, and Molkentin JD. Targeted inhibition of p38 mitogen-activated protein kinase antagonizes cardiac injury and cell death following ischemia-reperfusion in vivo. J Biol Chem 279: 15524-15530, 2004.
25. Kang PM, Yue P, Liu Z, Tarnavski O, Bodyak N, and Izumo S. Alterations in apoptosis regulatory factors during hypertrophy and heart failure. Am J Physiol Heart Circ Physiol 287: H72-H80, 2004.
26. Kim SZ, Cho KW, and Kim SH. Modulation of endocardial natriuretic peptide receptors in right ventricular hypertrophy. Am J Physiol Heart Circ Physiol 277: H2280-H2289, 1999.
27. Klein I and Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 344: 501-509, 2001.
28. Kogler H, Hartmann O, Leineweber K, van Nguyen P, Schott P, Brodde OE, and Hasenfuss G. Mechanical load-dependent regulation of gene expression in monocrotaline-induced right ventricular hypertrophy in The rat. Circ Res 93: 230-237, 2003.
29. Korstjens IJ, Rouws CH, van der Laarse WJ, Van der ZL, and Stienen GJ. Myocardial force development and structural changes associated with monocrotaline induced cardiac hypertrophy and heart failure. J Muscle Res Cell Motil 23: 93-102, 2002.
30. Lame MW, Jones AD, Wilson DW, Dunston SK, and Segall HJ. Protein targets of monocrotaline pyrrole in pulmonary artery endothelial cells. J Biol Chem 275: 29091-29099, 2000.
31. Leineweber K, Brandt K, Wludyka B, Beilfuss A, Ponicke K, Heinroth-Hoffmann I, and Brodde OE. Ventricular hypertrophy plus neurohumoral activation is necessary to alter the cardiac β-adrenoceptor system in experimental heart failure. Circ Res 91: 1056-1062, 2002.
32. Levy D, Garrison RJ, Savage DD, Kannel WB, and Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322: 1561-1566, 1990.
33. Miyauchi T, Yorikane R, Sakai S, Sakurai T, Okada M, Nishikibe M, Yano M, Yamaguchi I, Sugishita Y, and Goto K. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ Res 73: 887-897, 1993.
34. Montoya J, Perez-Martos A, Garstka HL, and Wiesner RJ. Regulation of mitochondrial transcription by mitochondrial transcription factor A. Mol Cell Biochem 174: 227-230, 1997.
35. Morisco C, Sadoshima J, Trimarco B, Arora R, Vatner DE, and Vatner SF. Is treating cardiac hypertrophy salutary or detrimental: the two faces of Janus. Am J Physiol Heart Circ Physiol 284: H1043-H1047, 2003.
36. Park MT, Choi JA, Kim MJ, Um HD, Bae S, Kang CM, Cho CK, Kang S, Chung HY, Lee YS, and Lee SJ. Suppression of extracellular signal-related kinase and activation of p38 MAPK are two critical events leading to caspase-8- and mitochondria-mediated cell death in phytosphingosine-treated human cancer cells. J Biol Chem 278: 50624-50634, 2003.
37. Ravingerova T, Barancik M, and Strniskova M. Mitogen-activated protein kinases: a new therapeutic target in cardiac pathology. Mol Cell Biochem 247: 127-138, 2003.
38. 2-terminal kinase-dependent activation of the mitochondrial pathway. Circ Res 92: 136-138, 2003.
39. Rong R, Ahn JY, Huang H, Nagata E, Kalman D, Kapp JA, Tu J, Worley PF, Snyder SH, and Ye K. PI3 kinase enhancer-Homer complex couples mGluRI to PI3 kinase, preventing neuronal apoptosis. Nat Neurosci 6: 1153-1161, 2003.
40. Seyfarth T, Gerbershagen HP, Giessler C, Leineweber K, Heinroth-Hoffmann I, Ponicke K, and Brodde OE. The cardiac β-adrenoceptor-G-protein(s)- adenylyl cyclase system in monocrotaline-treated rats. J Mol Cell Cardiol 32: 2315-2326, 2000.
41. Snijders AM, Nowak N, Segraves R, Blackwood S, Brown N, Conroy J, Hamilton G, Hindle AK, Huey B, Kimura K, Law S, Myambo K, Palmer J, Ylstra B, Yue JP, Gray JW, Jain AN, Pinkel D, and Albertson DG. Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet 29: 263-264, 2001.
42. Stoutfer SA, Guttman L, Suchman EA, and Suchman EA. Measurement and Prediction. Princeton, NJ: Princeton Univ. Press, 1950.
43. Tusher VG, Tibshirani R, and Chu G. Significance analysis of microarrays applied to the ionizing radiation response. PNAS 98: 5116-5121, 2001.
44. van den IJssel P, Eijk P, Hopmans E, Kasanmoentalib S, and Ylstra B. Quality of in-house made high-density microarrays. In: Encyclopedia of Diagnostic Genomics and Proteomics, edited by Fuchs J and Podda M. New York: Marcel Dekker, 2004, p. 1108-1112.
45. Versluis JP, Heslinga JW, Sipkema P, and Westerhof N. Contractile reserve but not tension is reduced in monocrotaline-induced right ventricular hypertrophy. Am J Physiol Heart Circ Physiol 286: H979-H984, 2004.
46. Vikstrom KL, Bohlmeyer T, Factor SM, and Leinwand LA. Hypertrophy, pathology, and molecular markers of cardiac pathogenesis. Circ Res 82: 773-778, 1998.
47. Wassen FW, Schiel AE, Kuiper GG, Kaptein E, Bakker O, Visser TJ, and Simonides WS. Induction of thyroid hormone-degrading deiodinase in cardiac hypertrophy and failure. Endocrinology 143: 2812-2815, 2002.
48. Weiss JN, Korge P, Honda HM, and Ping P. Role of the mitochondrial permeability transition in myocardial disease. Circ Res 93: 292-301, 2003.
49. Wilson DW, Segall HJ, Pan LC, Lame MW, Estep JE, and Morin D. Mechanisms and pathology of monocrotaline pulmonary toxicity. Crit Rev Toxicol 22: 307-325, 1992.
50. Wolkart G, Stromer H, and Brunner F. Calcium handling and role of endothelin-1 in monocrotaline right ventricular hypertrophy of the rat. J Mol Cell Cardiol 32: 1995-2005, 2000.
51. Yoshihara F, Nishikimi T, Horio T, Yutani C, Nagaya N, Matsuo H, Ohe T, and Kangawa K. Ventricular adrenomedullin concentration is a sensitive biochemical marker for volume and pressure overload in rats. Am J Physiol Heart Circ Physiol 278: H633-H642, 2000.